A Cannabinoid-Tolerance Review Identified a Human Imaging Gap for Receptor Desensitization
A 2023 review distinguished evidence of CB1 receptor downregulation from evidence of reduced receptor responsiveness, highlighting a gap in directly assessing human desensitization through neuroimaging. Receptor availability and functional sensitivity are different measurements.
The evidence crossed species and assay types
The review discussed rodents, nonhuman primates and humans. It described downregulation evidence in tolerant animals and people, alongside strong desensitization evidence in rodent models. Those statements should retain their different experimental foundations.
An imaging signal cannot answer every function question
A method used to assess receptor-related availability does not automatically quantify how effectively a receptor signals when stimulated. The review's identified probe gap therefore limits claims that one human scan directly demonstrates every proposed tolerance mechanism.
Intracellular pathways add further distinctions
The authors considered kinases, arrestin recruitment and receptor trafficking, as well as sex-related differences. These mechanisms help organize research without supplying a single personal tolerance score. Changes in one pathway cannot be inferred solely from a history of frequent use.
Interpreting the evidence
The review supports specifying whether a claim concerns receptor availability, signaling response or behavior. It does not validate imaging as an individual impairment or dependence test, and it does not erase the gap between rodent mechanisms and direct human measurement.
Related reading: interpreting cannabis tolerance claims.
Research reference
Piscura MK; Henderson-Redmond AN; Barnes RC; Mitra S; Guindon J; Morgan DJ (2023). Mechanisms of cannabinoid tolerance. Biochemical pharmacology. doi:10.1016/j.bcp.2023.115665.
This analysis draws on the supplied review abstract.
